Oklahoma 2022 Regular Session

Oklahoma Senate Bill SB1275 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
	3	+	SB1275 HFLR Page 1
	4	+	BOLD FACE denotes Committee Amendments. 1
	5	+	2
	6	+	3
	7	+	4
	8	+	5
	9	+	6
	10	+	7
	11	+	8
	12	+	9
	13	+	10
	14	+	11
	15	+	12
	16	+	13
	17	+	14
	18	+	15
	19	+	16
	20	+	17
	21	+	18
	22	+	19
	23	+	20
	24	+	21
	25	+	22
	26	+	23
	27	+	24
3	28
4		-	An Act
5		-	ENROLLED SENATE
	29	+	HOUSE OF REPRESENTATIVES - FLOOR VERSION
	30	+
	31	+	STATE OF OKLAHOMA
	32	+
	33	+	2nd Session of the 58th Legislature (2022)
	34	+
	35	+	ENGROSSED SENATE
6	36		BILL NO. 1275 By: Howard of the Senate
7	37
8	38		and
9	39
10	40		Wallace of the House
11		-
12	41
13	42
14	43
15	44		An Act relating to opioid abatement; amending 74 O.S.
16	45		2021, Sections 30.5 and 30.8, which relate to the
17	46		Political Subdivisions Opioid Ab atement Grants Act;
18	47		modifying scope of certain defined terms; deleting
19	48		definition; revising criteria for allocatin g opioid
20	49		grant awards to eligible participants ; providing for
21	50		the reimbursement of attorney fees and allowable
22	51		expenses associated with legal services agreements;
23	52		requiring initial opioid grant awards to be listed on
24	53		a distribution table; updating statutory language;
25	54		and declaring an emergency .
26	55
27	56
28		-
29		-
30		-
31		-	SUBJECT: Opioid abatement
32		-
33	57		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
34		-
35	58		SECTION 1. AMENDATORY 74 O.S. 2021, Section 30.5, is
36	59		amended to read as follows:
37		-
38	60		Section 30.5. As used in the Political S ubdivisions Opioid
39	61		Abatement Grants Act:
40		-
41	62		1. “Approved purpose” and “approved purposes” mean evidence-
42	63		based, forward-looking strategies, programming and services used to:
43		-
44	64		a. expand the availability of treatment for individuals
45	65		affected by opioid use diso rders, co-occurring
46	66		substance use disorders and mental health issues ,
47	67
48		-	ENR. S. B. NO. 1275 Page 2
	68	+	SB1275 HFLR Page 2
	69	+	BOLD FACE denotes Committee Amendments. 1
	70	+	2
	71	+	3
	72	+	4
	73	+	5
	74	+	6
	75	+	7
	76	+	8
	77	+	9
	78	+	10
	79	+	11
	80	+	12
	81	+	13
	82	+	14
	83	+	15
	84	+	16
	85	+	17
	86	+	18
	87	+	19
	88	+	20
	89	+	21
	90	+	22
	91	+	23
	92	+	24
49	93
50	94		b. develop, promote and provide evidence-based opioid use
51	95		prevention strategies,
52		-
53	96		c. provide opioid use disorder and co-occurring substance
54	97		use disorder avoidance and awareness educatio n,
55		-
56	98		d. decrease the oversupply of licit and illicit opioids,
57		-
58	99		e. support recovery from addiction services performed by
59	100		qualified and approp riately licensed providers,
60		-
61	101		f. treat opioid use, abuse and disorders , including early
62	102		intervention screening, counse ling and support,
63		-
64	103		g. support individuals in treatment and recovery from
65	104		opioid use, abuse and disorder,
66		-
67	105		h. provide programs or services to c onnect individuals
68	106		with opioid use, abuse or disorder, or who are at risk
69	107		of developing opioid use disorder, co -occurring
70	108		substance use disorder and mental health issues, with
71	109		treatment and counseling programs and services,
72		-
73	110		i. address the needs of individu als who are involved, or
74	111		who are at risk of becoming involved, in the criminal
75	112		justice system due to opioid use, abuse or disorder
76	113		through programs or services in municipal and county
77	114		criminal judicial systems, including prearrest and
78	115		postarrest diversion programs, pretrial services and
79	116		drug or recovery courts,
80	117
	118	+	SB1275 HFLR Page 3
	119	+	BOLD FACE denotes Committee Amendments. 1
	120	+	2
	121	+	3
	122	+	4
	123	+	5
	124	+	6
	125	+	7
	126	+	8
	127	+	9
	128	+	10
	129	+	11
	130	+	12
	131	+	13
	132	+	14
	133	+	15
	134	+	16
	135	+	17
	136	+	18
	137	+	19
	138	+	20
	139	+	21
	140	+	22
	141	+	23
	142	+	24
	143	+
81	144		j. address the needs of pregnant or parenting women wit h
82	145		opioid use, abuse or disorder and their families ,
83	146		including babies with neo natal abstinence syndrome,
84		-
85	147		k. address the needs of parents and care givers caring for
86	148		babies with neonatal abstinence syndrome,
87		-
88	149		l. support efforts to prevent overprescribing and ensure
89	150		appropriate prescribing and dispensing of opioids,
90		-
91		-
92		-	ENR. S. B. NO. 1275 Page 3
93	151		l. m. support efforts to discourage or prevent misuse of
94	152		opioids, including the oversupp ly of licit and illicit
95	153		opioids,
96		-
97	154		m. n. support efforts to prevent or reduce overdose deaths
98	155		or other opioid-related harms, including through
99	156		increased availability and distribution of nalox one
100	157		and other drugs that treat overdoses for use by first
101	158		responders, persons who have experienced an overdose
102	159		event, families, schools, community -based service
103	160		providers, social workers and other members of the
104	161		public,
105		-
106	162		n. o. reimburse or fund law enforcem ent and emergency
107	163		responder expenditures relating to the opioid
108	164		epidemic, including costs of responding to emergency
109	165		medical or police calls for service, equipment,
110	166		treatment or response alternatives, mental health
111	167		response training and training for law en forcement and
	168	+
	169	+	SB1275 HFLR Page 4
	170	+	BOLD FACE denotes Committee Amendments. 1
	171	+	2
	172	+	3
	173	+	4
	174	+	5
	175	+	6
	176	+	7
	177	+	8
	178	+	9
	179	+	10
	180	+	11
	181	+	12
	182	+	13
	183	+	14
	184	+	15
	185	+	16
	186	+	17
	187	+	18
	188	+	19
	189	+	20
	190	+	21
	191	+	22
	192	+	23
	193	+	24
	194	+
112	195		emergency responders as to appropriate practices and
113	196		precautions when dealing with opioids or individuals
114	197		who are at risk of opioid overdose or death,
115		-
116	198		o. p. reimburse attorney fees and allowable expenses
117	199		directly related to opioid litigation incurred as part
118	200		of legal services agreements entered into before May
119	201		21, 2020,
120		-
121	202		q. support efforts to provide leadership, planning and
122	203		coordination to abate the opioid epidemic throu gh
123	204		activities, programs or strategies for prevention and
124	205		recovery models, including regional intergovernmental
125	206		efforts and not-for-profit agency suppor t,
126		-
127	207		p. r. support education of youths regarding the dangers of
128	208		opioid use, abuse and addiction,
129		-
130	209		q. s. fund training relative to any approved purpose,
131		-
132	210		r. t. monitor, surveil and eva luate opioid use, abuse or
133	211		disorder, or
134		-
135		-
136		-	ENR. S. B. NO. 1275 Page 4
137	212		s. u. provide opioid abatement as ide ntified by the Oklahoma
138	213		Opioid Abatement Board as consistent with the purpose
139	214		of this act the Political Subdivisions Opioid
140	215		Abatement Grants Act .
141		-
142	216		Provided that, such strategies, programming and services occurred on
143	217		or after January 1, 2006 2015;
	218	+	2. “Board” means the Oklahoma Opioid Abatement Board;
144	219
145		-	2. “Board” means the Oklahoma Opioid Abatement Board;
	220	+	SB1275 HFLR Page 5
	221	+	BOLD FACE denotes Committee Amendments. 1
	222	+	2
	223	+	3
	224	+	4
	225	+	5
	226	+	6
	227	+	7
	228	+	8
	229	+	9
	230	+	10
	231	+	11
	232	+	12
	233	+	13
	234	+	14
	235	+	15
	236	+	16
	237	+	17
	238	+	18
	239	+	19
	240	+	20
	241	+	21
	242	+	22
	243	+	23
	244	+	24
146	245
147	246		3. “Eligible participant ” means any political subdiv ision or
148	247		first responder organization that obtained legal representati on or
149	248		participated in litigation with pharmaceutical supply chain
150	249		participants prior to the effective date of this act impacted by the
151	250		opioid crisis;
152		-
153	251		4. “First responder organization” means a nonprofit
154	252		organization formed and in good standing under 501(c)(9) of the
155	253		Internal Revenue Code, whose primary function is to benefit public
156	254		safety employees;
157		-
158	255		5. “Nonapproved purpose” and “nonapproved purposes ” mean
159	256		strategies, programming and services not falling within the
160	257		definition of “approved purpose” approved purpose or “approved
161	258		purposes” approved purposes as defined in this act section;
162		-
163	259		6. 5. “Opioid funds” means all monetary amounts obtained
164	260		through a settlement or judgment by the Attorney General on behalf
165	261		of the State of Oklahoma this state related to opioid litigation
166	262		involving pharmaceutical supply chain participants, including the
167	263		Purdue Political Subdivisions Fund but excluding all other funds
168	264		received pursuant to the Purdue Settlement Agreement;
169		-
170	265		7. 6. “Opioid grant awards” means grants funded from the
171	266		Oklahoma Opioid Abate ment Revolving Fund, aw arded pursuant to the
172	267		provisions of this act the Political Subdivisions Opioid Abatement
173	268		Grants Act;
174	269
	270	+	SB1275 HFLR Page 6
	271	+	BOLD FACE denotes Committee Amendments. 1
	272	+	2
	273	+	3
	274	+	4
	275	+	5
	276	+	6
	277	+	7
	278	+	8
	279	+	9
	280	+	10
	281	+	11
	282	+	12
	283	+	13
	284	+	14
	285	+	15
	286	+	16
	287	+	17
	288	+	18
	289	+	19
	290	+	20
	291	+	21
	292	+	22
	293	+	23
	294	+	24
	295	+
175	296		8. 7. “Pharmaceutical supply chain ” means the process and
176	297		channels through which controlled substances are manufactured,
177	298		marketed, promoted, distributed o r dispensed;
178		-
179		-
180		-	ENR. S. B. NO. 1275 Page 5
181	299		9. 8. “Pharmaceutical supply chain participant” means any
182	300		entity that engages in or has engaged in the manufacture, marketing,
183	301		promotion, distribution or d ispensing of an opioid analgesic;
184		-
185	302		10. 9. “Political subdivision ” and “political subdivisions”
186	303		have the same meaning as provided in subparagraphs a, b, c and d of
187	304		paragraph 11 of Section 152 of Title 51 of the Oklahoma Statutes;
188		-
189	305		11. 10. “Purdue Political Subdivision Fund” means the Twelve
190	306		Million Five Hundred Thousand Dollars ($12,500,000.0 0) plus any
191	307		interest accrued thereon received from the Revive Oklahoma Health
192	308		Foundation consisting of funds from the Purdue Settlement Agreement
193	309		designed for distribu tion to political subdivisions which have
194	310		executed a release of le gal claims as required by the Purdue
195	311		Settlement Agreement; and
196		-
197	312		12. 11. “Purdue Settlement Agreement” means the settlement
198	313		agreement entered into by the State of Oklahoma this state and
199	314		Purdue Pharma L.P., Purdue Pharma, Inc. and the Purdue Frederick
200	315		Company on March 26, 2019, a nd approved by the Court on April 2,
201	316		2019.
202		-
203	317		SECTION 2. AMENDATORY 74 O.S. 2021, Section 30.8, is
204	318		amended to read as follows:
	319	+
	320	+	SB1275 HFLR Page 7
	321	+	BOLD FACE denotes Committee Amendments. 1
	322	+	2
	323	+	3
	324	+	4
	325	+	5
	326	+	6
	327	+	7
	328	+	8
	329	+	9
	330	+	10
	331	+	11
	332	+	12
	333	+	13
	334	+	14
	335	+	15
	336	+	16
	337	+	17
	338	+	18
	339	+	19
	340	+	20
	341	+	21
	342	+	22
	343	+	23
	344	+	24
205	345
206	346		Section 30.8. A. 1. The Oklahoma Opioid Abatement Board shall
207	347		conduct an initial disbursement of opioid grant awards to
208	348		participating eligible participants. Such opioid grant awards shall
209	349		be allocated amongst the different participati ng eligible
210	350		participants based on the following criteria, giving equal weight to
211	351		each criteria:
212		-
213	352		a. the number of people per capita suffering from opioid
214	353		use disorder in the participating political
215	354		subdivision, or in the absence of such information,
216	355		the opioid prescription rate in the political
217	356		subdivision compared to the national average opio id
218	357		prescription rate,
219		-
220	358		b. the number of opioid overdose deaths in the
221	359		participating political subdivision, and
222		-
223		-
224		-	ENR. S. B. NO. 1275 Page 6
225	360		c. the amount of opioids distributed within the
226	361		participating political subdivision , and
227		-
228	362		d. the amount of attorney fees and allowable expenses
229	363		associated with legal services agreemen ts directly
230	364		related to opioid litigation incurred as part of legal
231	365		services agreements entered into before May 21, 202 0.
232		-
233	366		2. Grant awards shall be subject to legal services agreements
234	367		entered into by participating eligible participants based on the
235	368		grant awards.
	369	+
	370	+	SB1275 HFLR Page 8
	371	+	BOLD FACE denotes Committee Amendments. 1
	372	+	2
	373	+	3
	374	+	4
	375	+	5
	376	+	6
	377	+	7
	378	+	8
	379	+	9
	380	+	10
	381	+	11
	382	+	12
	383	+	13
	384	+	14
	385	+	15
	386	+	16
	387	+	17
	388	+	18
	389	+	19
	390	+	20
	391	+	21
	392	+	22
	393	+	23
	394	+	24
236	395
237	396		3. Initial opioid grant awards as provided for in this
238	397		subsection shall be listed in an opioid grant award allocation
239	398		matrix distribution table reviewed and approved by the B oard to
240	399		ensure that such awards adhere to the crite ria as provided in this
241	400		subsection adopted by the Board.
242		-
243	401		B. Following the awarding of opioid grant awards pursuant to
244	402		subsection A of this section, any remaining une ncumbered balance in
245	403		the Oklahoma Opioid Abatement Revolving Fund shall be available to
246	404		the Board to award as gra nts to eligible participants; provided such
247	405		awards shall only be utilized by eligible participants for approved
248	406		purposes.
249		-
250	407		C. In the event an e ligible participant merges, dissolves or
251	408		ceases to exist, any remaining allocations of an awarded opioid
252	409		grant award in excess of Five Hundred Dollars ($500.00) shall be
253	410		reallocated equitably based on the composition of the successor
254	411		eligible participant o r the successor eligible participants .
255		-
256	412		SECTION 3. It being immediately ne cessary for the preserv ation
257	413		of the public peace, health or safety, an emergency is hereby
258	414		declared to exist, by reason whereof this act shall take effect and
259	415		be in full force from and after its passage and approval.
260	416
261		-
262		-	ENR. S. B. NO. 1275 Page 7
263		-	Passed the Senate the 22nd day of March, 2022.
264		-
265		-
266		-
267		-	Presiding Officer of the Senate
268		-
269		-
270		-	Passed the House of Representatives t he 20th day of April, 2022.
271		-
272		-
273		-
274		-	Presiding Officer of the House
275		-	of Representatives
276		-
277		-	OFFICE OF THE GOVERNOR
278		-	Received by the Office of the Governor this _______ _____________
279		-	day of _________________ __, 20_______, at _______ o'clock _______ M.
280		-	By: _______________________________ __
281		-	Approved by the Governor of the State of Oklahoma this _____ ____
282		-	day of _________________ __, 20_______, at _______ o'clock _______ M.
283		-
284		-	_________________________________
285		-	Governor of the State of Oklahoma
286		-
287		-
288		-	OFFICE OF THE SECRETARY OF STATE
289		-	Received by the Office of the Secretary of State this _______ ___
290		-	day of __________________, 20 _______, at _______ o'clock _______ M.
291		-	By: _______________________________ __
	417	+	COMMITTEE REPORT BY: COMMITTEE ON ALC OHOL, TOBACCO AND CONTROLLED
	418	+	SUBSTANCES, dated 04/14/2022 - DO PASS.